Form 4: Linda Maxwell Acquires Stock Options in ImmunityBio, Inc.

Linda Maxwell, a Director at ImmunityBio, Inc., reports the acquisition of stock options exercisable for 77,633 shares of common stock.

Summary

• On June 11, 2024, Linda Maxwell, a Director of ImmunityBio, Inc. (IBRX), acquired stock options to purchase 77,633 shares of common stock at an exercise price of $5.96.
• The options vest on the earlier of June 11, 2025, or the day before the next annual meeting of stockholders, contingent upon continued service as a Service Provider as defined in the Issuer's 2015 Equity Incentive Plan.
• Following the transaction, Maxwell directly owns 77,633 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock option acquisition. The vesting conditions suggest a continued commitment from the director.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future performance.

Future Outlook

The vesting of the stock options is contingent upon Linda Maxwell's continued service as a Service Provider, suggesting an ongoing commitment to the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies. This filing indicates a change in beneficial ownership for a director of ImmunityBio.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders, potentially signaling confidence in the company's future prospects.

Key Dates